Zydus to acquire Assertio in $166m deal
The offer was approved by Assertio’s Board of Directors, following a revised merger agreement process and is considered a “superior proposal” compared to the previous agreement with Garda
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.